Anna Berkenblit, Chief Scientific and Medical Officer of Pancreatic Cancer Action Network, shared a post on LinkedIn:
“I’ve recently highlighted emerging data on daraxonrasib, an oral targeted therapy that has demonstrated a meaningful improvement in overall survival, approximately doubling survival compared with standard intravenous chemotherapy in patients with previously treated metastatic pancreatic cancer. These findings represent an important advance in the evolving treatment landscape for pancreatic cancer, particularly for patients who have limited options after first-line therapy.
I’m thrilled to share that information is now available on the Expanded Access Program (EAP). Read the latest from PanCAN”
Other articles featuring Anna Berkenblit on OncoDaily.